Which returned more over the last year, IBB or VCIT?

In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and VCIT returned −1.2%, so IBB returned more. One year is one year; the longer windows are in the table.

Which is cheaper, IBB or VCIT?

IBB charges 0.44% a year and VCIT charges 0.03%, so VCIT is cheaper. Fees come from each fund's prospectus.

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

IBB vs VCIT: how they differ

IBB and VCIT hold 0% of their weight in the same names, and IBB returned more over the year.

iShares Biotechnology ETF and Vanguard Intermediate-Term Corporate Bond Index Fund.

What they hold in common

By the books each fund has filed, IBB and VCIT hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in IBB	Only in VCIT
Vertex Pharmaceuticals, Inc. 8.09%	Amazon.com Inc 0.31%
Amgen, Inc. 7.84%	Boeing Co/The 0.28%
Gilead Sciences, Inc. 6.85%	Meta Platforms Inc 0.28%
Regeneron Pharmaceuticals, Inc. 4.91%	Bank of America Corp 0.27%
Argenx SE 3.76%	Oracle Corp 0.27%
Alnylam Pharmaceuticals, Inc. 3.12%	Pfizer Investment Enterprises Pte Ltd 0.27%
Natera, Inc. 2.89%	Anheuser-Busch Cos LLC / Anheuser-Busch 0.27%
Revolution Medicines, Inc. 2.78%	JPMorgan Chase & Co 0.25%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

IBB and VCIT on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
	IBB iShares Biotechnology ETF	VCIT Vanguard Intermediate-Term Corporate Bond Index Fund
Where it sits	Core index fund	Core index fund
Issuer	iShares	Vanguard
What it is	Biotechnology	Intermediate-Term Corporate Bond
Total return, 1 year	+41.5%	−1.2%
S&P 500 over the same days	+17.5%	+17.5%
Gap to the S&P 500	+24.0 pts	−18.7 pts
Expense ratio	0.44%	0.03%
Holdings	248	2302

IBB in plain words

IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.

VCIT in plain words

VCIT is a bond fund tracking the Intermediate-Term Corporate Bond. Over the year to Sep 11, 2026 it returned −1.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. It sat 3.4% below its high of Feb 27, 2026 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, IBB or VCIT?: In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and VCIT returned −1.2%, so IBB returned more. One year is one year; the longer windows are in the table.
Which is cheaper, IBB or VCIT?: IBB charges 0.44% a year and VCIT charges 0.03%, so VCIT is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

IBB against VCIT, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, IBB against VCIT, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-VCIT Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources